Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersPharmacotherapy for anxiety disorders in children and adolescentsContemporary assessment and pharmacotherapy of Tourette syndromeDevelopment and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment ProfileChildren with obsessive-compulsive disorder: are they just "little adults"?Pharmacotherapy for anxiety disorders in children and adolescentsCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersExcessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic reviewLack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autismAre child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials.Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods.Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial.Managing obsessive compulsive disorder: in children and adolescents.Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence?Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).Evidence-based pharmacotherapy of obsessive-compulsive disorder.Pharmacotherapies in the management of obsessive-compulsive disorder.A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Still Struggling: characteristics of youth with OCD who are partial responders to medication treatment.Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trialAssessment and management of treatment-refractory obsessive-compulsive disorder in children.A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette's disorder.The use of selective serotonin reuptake inhibitors in children and adolescents with major depression.Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations.Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial.Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trialPharmacological treatment options for panic disorder in children and adolescents.Fluvoxamine in the treatment of anxiety disorders.Pediatric obsessive-compulsive disorder: a guide to assessment and treatment.Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disordersPharmacological treatment of adolescent pathological gamblingThe reliability and validity of a Japanese version of symptom checklist 90 revised.The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods.Do all obsessive-compulsive disorder subtypes respond to medication?A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments.The Nordic long-term OCD treatment study (NordLOTS): rationale, design, and methods.12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.Advances in pharmacotherapy for pediatric anxiety disorders.Efficacy and safety of antidepressant drug treatment in children and adolescents.
P2860
Q22305681-36E13932-74FF-4B56-B484-966BC7439DC0Q24239941-739A1D47-11A8-4DB3-8A97-15018C69F538Q24607941-123DDD7C-E4DB-40BC-A1AA-7BADE1917F11Q24623483-DE5702E1-D212-4514-B108-FBDACD712323Q24650906-44668C23-C1C7-4143-9C62-48E1C60F1338Q26853715-25A00AE5-8227-437D-B0B3-F050502BE165Q27009995-95068DED-E7F7-4893-B155-3BD5556F3774Q27021267-3A88E0F7-740A-43CF-B929-D4DC07F9CF31Q28247116-B17295F1-A3C3-4B17-AE75-A80900DE5404Q33350235-3891B3C7-8D86-4DF5-BD3B-65A51817EEE0Q33638578-7088257E-54AE-42D6-8A17-F7DF9E99A4D6Q33751389-8CAB7D76-3644-4EAE-8EC9-77AB81FD4992Q34064588-97630553-611E-48BE-9266-5AA065DAA4B8Q34124607-3326387E-247A-4FC1-8733-C3A76C0998F6Q34147816-8FC9C5C0-B4FF-4827-BD6E-3D58D74153D3Q34245428-C32BE8E5-071D-427F-871E-9A5EEB475B06Q34547177-D71A000E-3556-4440-98E3-0127D7ED36A8Q34671104-5F52D789-502A-4EA8-8C75-8B9E3CBB57F4Q34865036-71591C57-9BBC-47F6-855B-C4E66ABC8203Q35098763-06222A16-AF4A-42F6-8E6A-7010EB59889CQ35568012-AD7B807A-B209-444D-9C13-3109FFC3616BQ35697831-168A9B0A-5044-4E1D-AFF9-4FDD753BC538Q35996794-60D2FABF-7EC1-42F3-9D1B-304BEDAB35B4Q36168586-51B62A6C-A834-4E95-91DC-F312DEA08FE2Q36195126-52E6D367-2212-4FDB-B1B6-BDE857C1AD3CQ36299893-692B1A59-98D7-4088-A08E-139D8EB8F049Q36390953-5B290653-A1CA-4B2A-A4EE-B369BB71C7EAQ36428485-BA5EA77E-034A-465D-BF23-C6D104444C60Q36713425-272D308D-B969-4B8C-BA77-3E82841995D7Q36871185-81E57E64-30D0-4538-9120-1493A5919C62Q36873932-FE1A5748-93B3-414D-B985-E9845EAF593DQ36904594-2580F401-7997-4DE2-A09A-08F245133335Q36970769-B6AD7B2D-D418-4961-BF3A-5B28466B56FBQ37107060-470E4DDA-AE8B-4ADC-807A-361821516AF8Q37127458-12F81EC4-EDA1-4616-A053-329364EF770CQ37165461-77A5E071-4B2D-483F-851C-1B62B76A7A19Q37426116-4FEA40F8-BB15-4998-8E50-79E18ECDF3C5Q37705750-15E4963F-1993-403F-B271-91E913493E3DQ37827822-EC470047-D298-4512-A044-286BBF0DE688Q37953772-A0A079B6-EB23-4F69-90AA-E9F6CCBF8BD2
P2860
Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Fluvoxamine for children and a ...... controlled, multicenter trial.
@ast
Fluvoxamine for children and a ...... controlled, multicenter trial.
@en
type
label
Fluvoxamine for children and a ...... controlled, multicenter trial.
@ast
Fluvoxamine for children and a ...... controlled, multicenter trial.
@en
prefLabel
Fluvoxamine for children and a ...... controlled, multicenter trial.
@ast
Fluvoxamine for children and a ...... controlled, multicenter trial.
@en
P2093
P1476
Fluvoxamine for children and a ...... controlled, multicenter trial.
@en
P2093
Claghorn JL
McConville BJ
P304
P356
10.1097/00004583-200102000-00017
P577
2001-02-01T00:00:00Z